A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent
small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as
NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or
refractory multiple myeloma (RRMM).